SAB Biotherapeutics Inc expected to post a loss of $1.16 a share - Earnings Preview

SAB Biotherapeutics

24/03/2025 20:28

SAB Biotherapeutics Inc SABS.OQ SABS.O is expected to show a fall in quarterly revenue when it reports  results on March 26 (estimated) for the period ending December 31 2024

The Miami Beach Florida-based  company is expected to report a 60.7% decrease in revenue to $120 thousand from $305 thousand a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

​LSEG's mean analyst estimate for SAB Biotherapeutics Inc is for a loss of $1.16 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for SAB Biotherapeutics Inc is $11.00​, above​ its last closing price of $1.72. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-1.09
-1.09
-1.12
Missed
-2.8
Jun. 30 2024
-1.12
-1.13
-0.79
Beat
30.1
Mar. 31 2024
-0.96
-0.96
-0.60
Beat
37.5​
Dec. 31 2023
-0.64
-0.62
-3.38
Missed
-445.2
​​Sep. 30 2023
-1.16
-1.17
-1.00
Beat
14.3
Jun. 30 2023
-1.48
-1.45
-1.40
Beat
3.4​
Mar. 31 2023
-0.80
-0.80
-1.50
Missed
-87.5
Dec. 31 2022
-0.35
-0.20
Beat
42.9

This summary was machine generated March 24 at 20:28 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)